A survey of treatment practice for patients with neuromyelitis optica spectrum disorder under satralizumab treatment using Japanese claims database
Not Applicable
- Conditions
- neuromyelitis optica spectrum disorder (NMOSD)
- Registration Number
- JPRN-UMIN000049131
- Lead Sponsor
- CHUGAI PHARMACEUTICAL CO.,LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients who reduced oral corticosteroid to 0 mg at day 360 without relapse under continuous satralizumab prescription
- Secondary Outcome Measures
Name Time Method